CHOOSE YOUR PLATFORM
Satrix Healthcare Innovation
The STOXX Global Breakthrough Healthcare index is composed of developed and emerging market companies that generate significant revenues from specific sectors focused on pushing the boundaries in medical treatment and technology.
JSE code: STXHLT. The Satrix Healthcare Innovation Feeder ETF seeks to track the performance of the STOXX Global Breakthrough Healthcare Index, which is composed of developed and emerging market companies that generate significant revenues from specific sectors focused on pushing the boundaries in medical treatment and technology.
Why Choose Satrix Healthcare Innovation
Investor Information As On 21 Nov 2024
| Net Asset Value per Satrix Healthcare Innovation Feeder ETF security | R 68.6053 |
| Distributable Amount per security | -0.0201 |
| Cash Contribution per Satrix Healthcare Innovation Feeder ETF basket | R 5 680.00 |
| Market Capitalisation of Satrix Healthcare Innovation Feeder ETF | R 73 874 992.18 |
| STOXX Global Breakthrough Healthcare Index | 137.40 |
| Total Expense Ratio | 0.48% |
Index Composition
- International Equity 100.00%
Satrix Healthcare Innovation Fund Performance
STEP 1. CONTRIBUTION
STEP 2. FUND
STEP 3. YEAR
VALUE
Fund Price
The investment performance is for illustrative purposes only and is calculated by taking into account JSE closing prices. Past performance is not indicative of future performance.
Select date range:
Start date :
End date :
Satrix ETF performance indicator:
The graph represents price performance using JSE closing prices per Satrix security and is relevant to each Satrix ETF (product) as offered by Satrix. Performance is for illustrative purposes only and past performance is not indicative of future performance. An individual’s investment performance and the Portfolio NAV may differ from the indicators in the graph as a result of other factors such as brokerage fees, acquisition prices, portfolio costs, management fees, dividend declarations and reinvestment, and withholding taxes, where applicable.
Performance Table
| 31 Oct 2024 | Fund * | Benchmark ** | CPI Inflation *** |
|---|---|---|---|
| Unannualized: | |||
| Since Inception (Jun 2022) | 23.57% | 25.14% | 0.0% |
| Annualized: | |||
| Since Inception | 9.15% | 9.73% | 5.04% |
| Year to Date | 0.5% | 0.74% | 3.02% |
| 1 Year | 19.83% | 20.22% | 2.93% |
| 3 Years | 0.0% | 0.0% | 5.47% |
| 5 Years | 0.0% | 0.0% | 4.92% |
| 7 Years | 0.0% | 0.0% | 4.76% |
| 10 Years | 0.0% | 0.0% | 4.92% |
- * Returns are calculated for lump sum investments. All dividends reinvested on ex-date.
- ** The benchmark is a total return index.
- *** This is based on the latest CPI numbers.
Fund Comparison Tool
The investment performance is for illustrative purposes only and is calculated by taking into account JSE closing prices. Past performance is not indicative of future performance.
Select fund to compare:
Select date range:
Start date :
End date :
Satrix ETF performance indicator:
The graph represents price performance using JSE closing prices per Satrix security and is relevant to each Satrix ETF (product) as offered by Satrix. Performance is for illustrative purposes only and past performance is not indicative of future performance. An individual’s investment performance and the Portfolio NAV may differ from the indicators in the graph as a result of other factors such as brokerage fees, acquisition prices, portfolio costs, management fees, dividend declarations and reinvestment, and withholding taxes, where applicable.
Effective Annual Cost
The Effective Annual Cost (EAC) is a measure which has been introduced to allow you to compare the cost you incur when you invest in different financial products. It is expressed as a percentage of your investment amount. The EAC is made up of four charges, which are added together, as shown in the table below. Some of the charges may vary, depending on your investment period. The EAC calculation assumes that an investor terminates his or her investment in the financial product at the end of the relevant periods shown in the table.